Skip to main content
Onxeo logo

Onxeo — Investor Relations & Filings

Ticker · ALONX ISIN · FR0010095596 LEI · 96950018AS30IUG0V528 PA Manufacturing
Open in API
Filings indexed 661 across all filing types
Latest filing 2026-05-04 Regulatory Filings
Country FR France
Listing PA ALONX

About Onxeo

https://www.onxeo.com/

Valerio Therapeutics, formerly Onxeo, is a biotechnology company developing next-generation precision-guided therapies for complex and underserved diseases. The company's core technology is its proprietary V-Body platform, which is based on two fully synthetic single-domain antibody (sdAb) libraries. This platform is engineered to create advanced drug conjugates that enable deep tissue penetration and highly precise therapeutic delivery. By integrating innovative target identification, antibody engineering, and cutting-edge linker and payload technologies, Valerio Therapeutics aims to develop treatments with superior efficacy and target engagement. The company's strategy involves advancing its therapeutic candidates to key development milestones before pursuing strategic partnerships for co-development and out-licensing.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Regulatory Filings
2026-05-04 French
Inside Information / Other news releases
Regulatory Filings
2026-05-04 English
Annual financial and audit reports / Terms of availability of the annual financial report
Earnings Release Classification · 85% confidence The document is a press release announcing Valerio Therapeutics’ 2025 annual results and summarizing key financial metrics (revenues, operating expenses, cash position) and strategic highlights. It does not contain the full annual report itself but provides an initial announcement of periodic financial results and refers readers to the full report on the company website. This matches the definition of an Earnings Release (ER) rather than an actual Annual Report (10-K) or a brief Report Publication Announcement (RPA). FY 2025
2026-04-29 English
Rapports financiers et d'audit annuels / Modalités de mise à disposition du rapport financier annuel
Earnings Release Classification · 85% confidence The document is a press release (“COMMUNIQUÉ DE PRESSE”) presenting Valerio Therapeutics’ annual 2025 results, key financial highlights (revenues, operating expenses, cash), strategic update and outlook. It summarizes performance and confirms the availability of the full annual report on the company’s website, without containing the full financial statements themselves. This aligns with an Earnings Release (initial announcement of periodical results), not the full Annual Report (10-K) nor merely a publication notice. Thus, it should be classified as an ER. FY 2025
2026-04-29 French
Informations privilégiées / Autres communiqués
Board/Management Information Classification · 100% confidence The document is a press release announcing the appointment of a new observer to the Board of Directors of Valerio Therapeutics, with the intention to propose him as a formal board member at the next general meeting. This falls under the category of announcements regarding changes in the company's board of directors or senior management.
2025-12-17 French
Inside Information / Other news releases
Board/Management Information Classification · 100% confidence The document is a press release announcing the appointment of a new Observer to the Board of Directors of Valerio Therapeutics. This falls under the category of board or management changes, which is explicitly defined as 'MANG'.
2025-12-17 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.